JP2016525548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525548A5 JP2016525548A5 JP2016529872A JP2016529872A JP2016525548A5 JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5 JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- desmopressin
- combination medicament
- hours
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857431P | 2013-07-23 | 2013-07-23 | |
| US61/857,431 | 2013-07-23 | ||
| PCT/US2014/047899 WO2015013454A1 (en) | 2013-07-23 | 2014-07-23 | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065913A Division JP7219736B2 (ja) | 2013-07-23 | 2020-04-01 | Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525548A JP2016525548A (ja) | 2016-08-25 |
| JP2016525548A5 true JP2016525548A5 (enExample) | 2017-08-31 |
Family
ID=51299056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529872A Pending JP2016525548A (ja) | 2013-07-23 | 2014-07-23 | Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2020065913A Active JP7219736B2 (ja) | 2013-07-23 | 2020-04-01 | Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065913A Active JP7219736B2 (ja) | 2013-07-23 | 2020-04-01 | Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9814753B2 (enExample) |
| EP (1) | EP3024474B1 (enExample) |
| JP (2) | JP2016525548A (enExample) |
| KR (3) | KR20160033220A (enExample) |
| CN (1) | CN105579057A (enExample) |
| AU (1) | AU2014293141A1 (enExample) |
| CA (1) | CA2919198A1 (enExample) |
| DK (1) | DK3024474T3 (enExample) |
| ES (1) | ES2910361T3 (enExample) |
| MX (1) | MX2016001030A (enExample) |
| WO (1) | WO2015013454A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| ES2638815T5 (en) | 2009-06-18 | 2025-06-26 | Acerus Pharmaceuticals Usa Llc | Safe desmopressin administration |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9925232B2 (en) | 2013-07-23 | 2018-03-27 | Serenity Pharmaceuticals, Llc | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| JP2017535567A (ja) | 2014-11-20 | 2017-11-30 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| EP3463307A4 (en) * | 2016-06-03 | 2020-01-15 | Velicept Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS |
| KR101877834B1 (ko) * | 2017-04-27 | 2018-07-12 | 주식회사 다산제약 | 미라베그론의 신규한 염 및 이의 제조방법 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| IL101243A (en) | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| DE69831421T2 (de) | 1997-12-02 | 2006-06-22 | Archimedes Development Ltd. | Zusammensetzungen zur nasalen verabreichung |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| EP2578252B1 (en) | 2000-11-30 | 2019-01-09 | Valeritas, Inc. | Device with substantially freely movable micro-probe over the housing |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| DK1559427T3 (da) * | 2002-11-07 | 2011-04-26 | Astellas Pharma Inc | Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel |
| EP2322195A2 (en) | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
| CN101829319A (zh) | 2003-12-08 | 2010-09-15 | Cpex药品公司 | 用于胰岛素治疗的药用组合物及方法 |
| DE102005016981A1 (de) | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| CA2633570A1 (en) | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
| JPWO2007083640A1 (ja) * | 2006-01-18 | 2009-06-11 | 杏林製薬株式会社 | 頻尿及び尿失禁の予防又は治療剤 |
| AU2008283929B2 (en) | 2007-08-06 | 2013-10-10 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| CN101648017A (zh) | 2008-08-12 | 2010-02-17 | 许洁 | 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物 |
| EP2361092A4 (en) | 2008-09-04 | 2012-07-11 | Anthony I Rozmanith | HEALTH CARE |
| US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| PT2381923T (pt) | 2008-12-22 | 2018-11-13 | Serenity Pharmaceuticals Llc | Administração intranasal de desmopressina |
| ES2638815T5 (en) | 2009-06-18 | 2025-06-26 | Acerus Pharmaceuticals Usa Llc | Safe desmopressin administration |
| WO2011043942A1 (en) * | 2009-10-07 | 2011-04-14 | Merck Sharp & Dohme Corp. | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
| US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US9522129B2 (en) * | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| CN107157991A (zh) | 2012-03-19 | 2017-09-15 | 韦尔斯利医药有限公司 | 用于缓解尿频的延长释放制剂及其使用方法 |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| GB201312155D0 (en) | 2013-07-05 | 2013-08-21 | Ucl Business Plc | Therapeutic invention |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| US9925232B2 (en) | 2013-07-23 | 2018-03-27 | Serenity Pharmaceuticals, Llc | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| MX2016002705A (es) | 2013-09-03 | 2016-09-06 | G2B Pharma Inc | Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides. |
| JP2017535567A (ja) | 2014-11-20 | 2017-11-30 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
-
2014
- 2014-07-23 CN CN201480052301.7A patent/CN105579057A/zh active Pending
- 2014-07-23 EP EP14748451.3A patent/EP3024474B1/en active Active
- 2014-07-23 US US14/338,554 patent/US9814753B2/en not_active Expired - Fee Related
- 2014-07-23 AU AU2014293141A patent/AU2014293141A1/en not_active Abandoned
- 2014-07-23 KR KR1020167004515A patent/KR20160033220A/ko not_active Ceased
- 2014-07-23 CA CA2919198A patent/CA2919198A1/en active Pending
- 2014-07-23 DK DK14748451.3T patent/DK3024474T3/da active
- 2014-07-23 MX MX2016001030A patent/MX2016001030A/es unknown
- 2014-07-23 ES ES14748451T patent/ES2910361T3/es active Active
- 2014-07-23 KR KR1020247002750A patent/KR20240015735A/ko not_active Ceased
- 2014-07-23 KR KR1020217025792A patent/KR20210103589A/ko not_active Ceased
- 2014-07-23 JP JP2016529872A patent/JP2016525548A/ja active Pending
- 2014-07-23 WO PCT/US2014/047899 patent/WO2015013454A1/en not_active Ceased
-
2017
- 2017-11-13 US US15/811,384 patent/US10568927B2/en active Active
-
2020
- 2020-04-01 JP JP2020065913A patent/JP7219736B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525548A5 (enExample) | ||
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| JP2013121983A5 (enExample) | ||
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2016185995A5 (enExample) | ||
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| JP2016539921A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2016519107A5 (enExample) | ||
| JP2013520448A5 (enExample) | ||
| JP2019514990A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| JP2014520874A5 (enExample) | ||
| JP2020500930A5 (enExample) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| JP2016525147A5 (enExample) | ||
| KR101896441B1 (ko) | 국소투여형의 연하장애 개선용 의약품 | |
| JP2016504361A5 (enExample) | ||
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
| JP2015515971A5 (enExample) | ||
| JP2017513866A5 (enExample) |